Source: Cytiva
As biologics like monoclonal antibodies expand into more treatments, the shift toward convenient subcutaneous delivery is creating new manufacturing hurdles. Higher-concentration formulations can strain processes like filtration, mixing, and filling, impacting product quality, yield, and efficiency.
This white paper explores how Cytiva and others are addressing these challenges through optimized processes and adaptable manufacturing solutions to support evolving drug delivery needs.
Continue reading to understand the key challenges of high-concentration biologics and how manufacturers can optimize processes to deliver better patient-friendly therapies.
Offered Free by: Bioprocess Online
See All Resources from: Bioprocess Online
